Targeted Microbubbles for Thrombus Penetration and Disruption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for removing occlusive thrombi and vascular plaques are inefficient, costly, and pose risks, with microbubbles struggling to access thrombus interiors due to size limitations and ultrasound treatments causing tissue damage.
Innovation Solution
Development of targeted microbubbles and nanodroplets with fibrin-binding and VCAM-1-binding ligands, capable of penetrating thrombi and plaques, which can be acoustically activated for enhanced sonothrombolytic efficiency and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional ultrasound is used to disrupt thrombi, then thrombus removal is achieved, but tissue damage occurs and the process is time-consuming
Solution Approach 1:
Targeted microbubbles serve as intermediary agents that accumulate at the thrombus site through fibrin-binding ligands, acting as acoustic amplifiers to enhance local ultrasound effects. This mediator approach allows concentrated energy delivery to the thrombus while protecting surrounding healthy tissue from damage.
Solution Approach 2:
The microbubbles are functionally differentiated by attaching fibrin-binding ligands specifically to their surface, creating local concentration at the thrombus interface. This local quality enhancement enables selective disruption of fibrin-rich thrombi while maintaining safety in surrounding tissues through targeted energy delivery.
2Productivity
If conventional microbubbles are used for sonothrombolysis, then thrombus disruption is enhanced, but access to thrombus interior is limited due to size
Solution Approach 1:
The microbubble population is segmented into different size fractions, with a significant portion residing in the 1-10 micron range that can penetrate into the porous thrombus matrix. This segmentation allows simultaneous achievement of good acoustic amplification (from larger bubbles) and deep tissue penetration (from smaller bubbles).
Solution Approach 2:
The physical parameter of microbubble size is optimized to fall within 1-10 microns, balancing acoustic resonance properties for efficient energy absorption with sufficient smallness to penetrate the porous thrombus interior. This parameter optimization resolves the contradiction between effectiveness and accessibility.
3Productivity
If non-targeted microbubbles are used, then general thrombus disruption is achieved, but specificity is reduced and background signal increases
Solution Approach 1:
Fibrin-binding ligands are selectively attached to the microbubble surface, creating local functional quality that enables specific recognition and accumulation at fibrin-rich thrombus sites. This local quality enhancement provides both targeted disruption capability and high detection specificity with low background signal.
Solution Approach 2:
The fibrin-binding ligands act as intermediary molecules that mediate between the microbubble and fibrin targets, enabling specific interaction at the thrombus interface. This intermediary mechanism ensures both effective thrombus disruption and high imaging specificity through selective accumulation.
4Productivity
If traditional thrombus removal methods are used, then occlusive thrombi are removed, but the process is costly and time-consuming
Solution Approach 1:
The patent replaces mechanical/thrombolytic systems (catheter-based mechanical disruption or systemic thrombolytics) with an acoustic field-based system. Ultrasound energy delivered through targeted microbubbles provides a non-invasive, rapid alternative that eliminates the need for complex mechanical interventions and reduces treatment time.
Solution Approach 2:
Pulsed ultrasound delivery is employed, where energy is applied in periodic pulses rather than continuously. This periodic action allows efficient thrombus disruption through cumulative acoustic effects while minimizing total energy exposure time, thereby reducing overall treatment duration and cost.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The targeted microbubbles and nanodroplets improve detection and disruption of thrombi and plaques, offering increased specificity and reduced tissue damage, with enhanced stability and clinical efficacy.
Implementation Method 1
Ultrasound can be used to disrupt thrombi; however, there is a trade-off between time/efficiency and damage to healthy tissue. Reagents, such as microbubbles, that can locally amplify the sound can accelerate disruption while keeping delivered energy low.
Implementation Method 2
Ultrasound can be used to disrupt thrombi; however, there is a trade-off between time/efficiency and damage to healthy tissue.
Implementation Method 3
Fibrin, also called Factor Ia, is a fibrous, non-globular protein involved in the clotting of blood. Fibrin is present at high concentrations in both venous and arterial thrombosis providing high sensitivity to fibrin-targeting therapies.
Implementation Method 4
Expression of endothelial cell adhesion molecules, e.g., vascular cell adhesion molecule-1 (VCAM-1), has been shown to play an important role in recruitment of leukocytes and is often increased at sites of pathological inflammation.
Data Source
AI summary
The invention provides nanodroplets labeled with targeting ligands that are useful in the detection and treatment of vascular thromboses (e.g., fibrin clots) and vascular plaques, or related diseases and conditions, as well as methods of preparation and use thereof.